[go: up one dir, main page]

WO2018193090A3 - Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci - Google Patents

Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci Download PDF

Info

Publication number
WO2018193090A3
WO2018193090A3 PCT/EP2018/060185 EP2018060185W WO2018193090A3 WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3 EP 2018060185 W EP2018060185 W EP 2018060185W WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
preparation
eliglustat hemitartrate
eliglustat
hemitartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/060185
Other languages
English (en)
Other versions
WO2018193090A2 (fr
Inventor
Kanaram Hanumanprasad KUMAWAT
Brijesh Rajendrakumar PATEL
Nilesh Mansukhlal Thumar
Joseph Prabahar UPADHYAY
Joseph Prabahar Koilpillai
Virendrakumar Agarwal
Parva Yogeshchandra Purohit
Arif Badrulhusan Siddiqui
Krushnakant Natvarbhai PATEL
Vipul Veljibhai GONDALIYA
Ankit Ramjibhai BUHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amneal Pharmaceuticals Co GmbH
Original Assignee
Amneal Pharmaceuticals Co GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amneal Pharmaceuticals Co GmbH filed Critical Amneal Pharmaceuticals Co GmbH
Publication of WO2018193090A2 publication Critical patent/WO2018193090A2/fr
Publication of WO2018193090A3 publication Critical patent/WO2018193090A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci. Elle concerne également des compositions pharmaceutiques stables à forme amorphe d'hémitartrate d'eliglustat comprenant la forme amorphe d'hémitartrate d'eliglustat, ainsi que leurs utilisations.
PCT/EP2018/060185 2017-04-21 2018-04-20 Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci Ceased WO2018193090A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721014151 2017-04-21
IN201721014151 2018-03-05

Publications (2)

Publication Number Publication Date
WO2018193090A2 WO2018193090A2 (fr) 2018-10-25
WO2018193090A3 true WO2018193090A3 (fr) 2019-01-03

Family

ID=62111029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/060185 Ceased WO2018193090A2 (fr) 2017-04-21 2018-04-20 Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Country Status (1)

Country Link
WO (1) WO2018193090A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521366A (zh) 2009-11-27 2021-03-19 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐
CN110759885B (zh) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 制备光活依格鲁特的方法
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
WO2020194138A1 (fr) * 2019-03-22 2020-10-01 Piramal Enterprises Limited Procédé amélioré pour la préparation d'éliglustat et de son intermédiaire
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (fr) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (fr) * 2009-11-27 2011-06-03 Genzyme Corporation Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453978C (fr) 2001-07-16 2011-10-11 Genzyme Corporation Synthese d'inhibiteurs de l'udp-glucose : n-acylsphingosine glycosyltransferase
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
CA2954030A1 (fr) 2014-07-03 2016-01-07 Dr. Reddy's Laboratories Limited Forme amorphe d'hemitartrate d'eliglustat
CN105646442A (zh) 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (fr) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles constituant des ligands du recepteur de l'adenosine
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (fr) * 2009-11-27 2011-06-03 Genzyme Corporation Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", 2 November 2017, article CHEMICAL ABSTRACTS OHIO: "/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", XP055491732 *

Also Published As

Publication number Publication date
WO2018193090A2 (fr) 2018-10-25

Similar Documents

Publication Publication Date Title
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
MA45809A (fr) Promédicaments de pth
WO2019133770A3 (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
WO2013091775A3 (fr) Utilisation de dérivés du cyclohéxanol comme principes actifs antimicrobiens
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
EP4252848A3 (fr) Oxystérols et leurs procédés d'utilisation
EP4609866A3 (fr) Oxystérols et leurs procédés d'utilisation
WO2017191130A3 (fr) Inhibiteurs d'arginase et leurs applications thérapeutiques
WO2018224063A3 (fr) Formes à l'état solide d'élagolix
MX383804B (es) Derivados de piperidina.
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
EP3694330A4 (fr) Dérivés d'indazolyl-spiro [2.2]pentane-carbonitrile en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et leurs utilisations
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
WO2020127819A3 (fr) Composition pharmaceutique comprenant de l'apixaban
WO2015042414A8 (fr) Composés multicycliques et leurs procédés d'utilisation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
CA3031343C (fr) Sels de dérivés de 2, 6-diméthylpyrimidone et leurs utilisations
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
EP3760195A4 (fr) Composition comprenant du 2,3-butanediol en tant que principe actif
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2